Postmenopausal hormone use and skeletal fracture: Does the size of the benefit decrease with increasing age?

Noel S. Weiss, Miriam Treggiari

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Results of a recent meta-analysis of randomized trials suggest that, among postmenopausal women, the relative impact of hormone use in reducing the incidence of skeletal fracture declines with increasing age. We contend that: 1) the duration of the randomized trials in which older postmenopausal women were included was too short to adequately evaluate the impact of long-term hormone use on fracture risk; 2) randomized trials of hormone use in relation to a surrogate end point, bone mineral density, as well as nonrandomized studies of hormones and fracture risk, have documented a skeletal benefit associated with long-term hormone use among postmenopausal women irrespective of age; and 3) even if with increasing age there were a true decline in the relative benefit associated with the use of hormones, the size of the absolute reduction in fracture risk produced by hormone use among older postmenopausal women could be similar to or greater than that among younger postmenopausal women. For these reasons, we believe that when weighing the risks and benefits of the initiation or continuation of hormone therapy, a postmenopausal woman and her provider of health care need not consider her age when estimating the skeletal benefit such therapy can offer.

Original languageEnglish (US)
Pages (from-to)364-368
Number of pages5
JournalObstetrics and Gynecology
Volume100
Issue number2
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Hormones
Fracture Fixation
Women's Health
Bone Density
Meta-Analysis
Biomarkers
Delivery of Health Care
Incidence
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Postmenopausal hormone use and skeletal fracture : Does the size of the benefit decrease with increasing age? / Weiss, Noel S.; Treggiari, Miriam.

In: Obstetrics and Gynecology, Vol. 100, No. 2, 2002, p. 364-368.

Research output: Contribution to journalArticle

@article{2f75c0dbc9f74098aef4d7ec9a54fea0,
title = "Postmenopausal hormone use and skeletal fracture: Does the size of the benefit decrease with increasing age?",
abstract = "Results of a recent meta-analysis of randomized trials suggest that, among postmenopausal women, the relative impact of hormone use in reducing the incidence of skeletal fracture declines with increasing age. We contend that: 1) the duration of the randomized trials in which older postmenopausal women were included was too short to adequately evaluate the impact of long-term hormone use on fracture risk; 2) randomized trials of hormone use in relation to a surrogate end point, bone mineral density, as well as nonrandomized studies of hormones and fracture risk, have documented a skeletal benefit associated with long-term hormone use among postmenopausal women irrespective of age; and 3) even if with increasing age there were a true decline in the relative benefit associated with the use of hormones, the size of the absolute reduction in fracture risk produced by hormone use among older postmenopausal women could be similar to or greater than that among younger postmenopausal women. For these reasons, we believe that when weighing the risks and benefits of the initiation or continuation of hormone therapy, a postmenopausal woman and her provider of health care need not consider her age when estimating the skeletal benefit such therapy can offer.",
author = "Weiss, {Noel S.} and Miriam Treggiari",
year = "2002",
doi = "10.1016/S0029-7844(02)02046-X",
language = "English (US)",
volume = "100",
pages = "364--368",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Postmenopausal hormone use and skeletal fracture

T2 - Does the size of the benefit decrease with increasing age?

AU - Weiss, Noel S.

AU - Treggiari, Miriam

PY - 2002

Y1 - 2002

N2 - Results of a recent meta-analysis of randomized trials suggest that, among postmenopausal women, the relative impact of hormone use in reducing the incidence of skeletal fracture declines with increasing age. We contend that: 1) the duration of the randomized trials in which older postmenopausal women were included was too short to adequately evaluate the impact of long-term hormone use on fracture risk; 2) randomized trials of hormone use in relation to a surrogate end point, bone mineral density, as well as nonrandomized studies of hormones and fracture risk, have documented a skeletal benefit associated with long-term hormone use among postmenopausal women irrespective of age; and 3) even if with increasing age there were a true decline in the relative benefit associated with the use of hormones, the size of the absolute reduction in fracture risk produced by hormone use among older postmenopausal women could be similar to or greater than that among younger postmenopausal women. For these reasons, we believe that when weighing the risks and benefits of the initiation or continuation of hormone therapy, a postmenopausal woman and her provider of health care need not consider her age when estimating the skeletal benefit such therapy can offer.

AB - Results of a recent meta-analysis of randomized trials suggest that, among postmenopausal women, the relative impact of hormone use in reducing the incidence of skeletal fracture declines with increasing age. We contend that: 1) the duration of the randomized trials in which older postmenopausal women were included was too short to adequately evaluate the impact of long-term hormone use on fracture risk; 2) randomized trials of hormone use in relation to a surrogate end point, bone mineral density, as well as nonrandomized studies of hormones and fracture risk, have documented a skeletal benefit associated with long-term hormone use among postmenopausal women irrespective of age; and 3) even if with increasing age there were a true decline in the relative benefit associated with the use of hormones, the size of the absolute reduction in fracture risk produced by hormone use among older postmenopausal women could be similar to or greater than that among younger postmenopausal women. For these reasons, we believe that when weighing the risks and benefits of the initiation or continuation of hormone therapy, a postmenopausal woman and her provider of health care need not consider her age when estimating the skeletal benefit such therapy can offer.

UR - http://www.scopus.com/inward/record.url?scp=0036334251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036334251&partnerID=8YFLogxK

U2 - 10.1016/S0029-7844(02)02046-X

DO - 10.1016/S0029-7844(02)02046-X

M3 - Article

C2 - 12151165

AN - SCOPUS:0036334251

VL - 100

SP - 364

EP - 368

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 2

ER -